RT Journal Article
T1 Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.
A1 Morillas, Carlos
A1 Feliciano, Rosa
A1 Fernández Catalina, Pablo
A1 Ponte, Carla
A1 Botella, Marta
A1 Rodrigues, João
A1 Esmatjes, Enric
A1 Lafita, Javier
A1 Lizán, Luis
A1 Llorente, Ignacio
A1 Morales, Cristóbal
A1 Navarro-Pérez, Jorge
A1 Orozco-Beltran, Domingo
A1 Paz, Silvia
A1 Ramirez de Arellano, Antonio
A1 Cardoso, Cristina
A1 Tribaldos Causadias, Maribel
K1 HbA1c
K1 Cardiovascular risk
K1 Diabetes
K1 Discrete choice model
K1 Hypoglycemia
K1 Preferences
K1 Weight
K1 Willingness to pay
K1 Peso corporal
K1 Enfermedades cardiovasculares
K1 Diabetes mellitus tipo 2
K1 Hipoglucemia
K1 Pérdida de peso
AB OBJECTIVETo assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects.METHODSAn observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the conditional logit model.RESULTSThree-hundred and thirty (n=330) patients (49.7% female; mean age 62.4 [SD: 10.3] years, mean T2DM duration 13.9 [8.2] years, mean body mass index 32.5 [6.8] kg/m(2), 41.8% received oral + injected medication, 40.3% received oral, and 17.6% injected treatments) and 221 physicians from Spain and Portugal (62% female; mean age 41.9 [SD: 10.5] years, 33.5% endocrinologists, 66.5% primary-care doctors) participated. Patients valued avoiding a gain in bodyweight of 3 kg/6 months (WTP: €68.14 [95% confidence interval: 54.55-85.08]) the most, followed by avoiding one hypoglycemic event/month (WTP: €54.80 [23.29-82.26]). Physicians valued avoiding one hypoglycemia/week (WTP: €287.18 [95% confidence interval: 160.31-1,387.21]) the most, followed by avoiding a 3 kg/6 months gain in bodyweight and decreasing cardiovascular risk (WTP: €166.87 [88.63-843.09] and €154.30 [98.13-434.19], respectively). Physicians and patients were willing to pay €125.92 (73.30-622.75) and €24.28 (18.41-30.31), respectively, to avoid a 1% increase in glycated hemoglobin, and €143.30 (73.39-543.62) and €42.74 (23.89-61.77) to avoid nausea.CONCLUSIONBoth patients and physicians in Spain and Portugal are willing to pay for the health benefits associated with improved diabetes treatment, the most important being to avoid hypoglycemia and gaining weight. Decreased cardiovascular risk and weight reduction became the third most valued attributes for physicians and patients, respectively.
PB Dove Medical Press
SN 1177-889X (Online)
YR 2015
FD 2015-10-14
LK http://hdl.handle.net/10668/2108
UL http://hdl.handle.net/10668/2108
LA en
NO Morillas C, Feliciano R, Catalina PF, Ponte C, Botella M, Rodrigues J, et al. Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment. Patient Prefer Adherence. 2015; 9:1443-58
NO Journal Article;
DS RISalud
RD Apr 6, 2025